13 June 2013Patents

US Supreme Court strikes Myriad blow

The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Myriad decision applied in diagnostic claims case

6 November 2013 The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

Patents

ACLU files Supreme Court brief in Myriad case

29 January 2013 The American Civil Liberties Union (ACLU) has urged the US Supreme Court to invalidate Myriad Genetics’ patent claims over two human genes linked to breast and ovarian cancer.

Patents

Myriad: Keeping a low profile

1 December 2012 The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

Tesla ‘Robotaxi’ and ‘Cybercab’ TMs rebuffed by USPTO on eve of launch

UK-India trade deal is ‘missed opportunity’, say industry bodies

WATCH: Recent developments in design patent law

SEPs now searchable on WIPO’s global patent database

INTA 2025: San Diego to host largest post-COVID Annual Meeting

'Nothing can stand in the way of our work': Ukraine resumes IP system

Foley adds five-partner team from Perkins Coie and K&L Gates

WATCH: Finding a new balance in IP protection with trade secret protection

US Supreme Court strikes Myriad blow

More on this story

Editor's picks

Editor's picks

More articles